Literature DB >> 6292799

Morphine catalepsy in the rat: involvement of mu 1 (high affinity) opioid binding sites.

G S Ling, G W Pasternak.   

Abstract

Since the proposal of multiple classes of opiate receptors, much effort has been devoted to understanding the subtypes mediating specific opioid actions. Using the irreversible antagonist naloxazone, we have established a role for the high affinity (mu 1) sites in analgesia. These sites also appear important in opiate catalepsy. Control rats showed dramatic catalepsy following a high dose of morphine sulfate (100 mg/kg, s.c.). Rats whose high affinity (mu 1) sites had been blocked with naloxazone 24 h earlier, on the other hand, showed no evidence of catalepsy (P less than 0.01). Accordingly, catalepsy appears to involve the same receptors as analgesia, the higher affinity (mu 1) sites.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292799     DOI: 10.1016/0304-3940(82)90273-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

1.  Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats.

Authors:  Marianne Skov-Skov Bergh; Inger Lise Bogen; Nancy Garibay; Michael H Baumann
Journal:  Neuropharmacology       Date:  2019-04-06       Impact factor: 5.250

2.  Differential sensitivity of opioid-induced feeding to naloxone and naloxonazine.

Authors:  P E Mann; D Arjune; M T Romero; G W Pasternak; E F Hahn; R J Bodnar
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Central delta-opioid receptor interactions and the inhibition of reflex urinary bladder contractions in the rat.

Authors:  A Dray; L Nunan; W Wire
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

4.  Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats.

Authors:  Marianne Skov-Skov Bergh; Inger Lise Bogen; Nancy Garibay; Michael H Baumann
Journal:  Psychopharmacology (Berl)       Date:  2021-10-06       Impact factor: 4.415

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.